Investor Relations
Sep 14, 2018
OPKO Confirms Resumption of Common Stock Trading on Nasdaq MORE >>
Sep 11, 2018
OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock MORE >>
Sep 07, 2018
OPKO Comments on SEC Complaint MORE >>
Sep 04, 2018
OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients MORE >>

Press Releases

All Releases
OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017
May 08, 2017
MIAMI , May 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017 , after the close of the U.S. financial markets on Tuesday, May 9, 2017 .
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder
Mar 22, 2017
MIAMI , March 22, 2017 (GLOBE NEWSWIRE) -- OPKO Pharmaceuticals LLC , a subsidiary of OPKO Health, Inc. (NASDAQ:OPK) announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO's
OPKO Health's GeneDx to have Significant Presence at ACMG 2017
Mar 14, 2017
Launching New Genetic Tests in Multiple Indications Multiple Poster and Platform Presentations Highlight GeneDx' Broad Offerings in a Variety of Genetic Specialties MIAMI , March 14, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK)   announces that GeneDx, a subsidiary of OPKO Health , will
OPKO Health to Participate in the Barclays Global Healthcare Conference
Mar 14, 2017
MIAMI , March 14, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announces that senior management will participate at the Barclays Global Healthcare Conference taking place March 14-16, 2017 at Loew's Miami Beach Hotel .  Company management will deliver a corporate overview on
OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 
Mar 08, 2017
MIAMI , March 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) through its subsidiaries, Eirgen Pharma Limited , Ireland and OPKO Pharmaceuticals LLC , has received notification from the European Commission designating OPKO's oligonucleotide-based AntagoNAT (CUR-1916) an orphan medicinal
OPKO Subsidiary GenPath Women's Health Announces the Availability of ClariTest™
Mar 07, 2017
Non-invasive prenatal test that harnesses the power of massively parallel sequencing to screen for fetal chromosomal abnormalities
OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development
Mar 03, 2017
MIAMI , March 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced the appointment of Akhtar Ashfaq , MD, FACP, FASN to the position of Senior Vice President, Clinical Research and Development of OPKO Health's Renal Division, effective immediately.  In this role, Dr.
OPKO Health Reports 2016 Financial and Operating Results
Mar 01, 2017
Consolidated revenue for the year ended December 31, 2016 increased to $1,221.7 million from $491.7 million for the comparable period of 2015. Consolidated revenue of  $275.5 million for the three months ended December 31, 2016 was consistent with the comparable period of 2015 which was $276.2
OPKO Health's GeneDx Announces Participation in Illumina's iHope Program on International Rare Disease Day
Feb 28, 2017
MIAMI , Feb. 28, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), today announces that GeneDx, a subsidiary of OPKO Health , is proud to participate as a founding member in Illumina Inc.'s (NASDAQ:ILMN) iHope Network on International Rare Disease Day, which takes place today.
OPKO Health to Announce 2016 Fourth Quarter Financial Results on March 1, 2017
Feb 27, 2017
MIAMI , Feb. 27, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the fourth quarter ended December 31, 2016 after the close of the U.S.
OPKO Health to Participate at Upcoming Healthcare Investment Conferences
Feb 21, 2017
MIAMI , Feb. 21, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will participate at the 2017 RBC Capital Markets' Healthcare Conference taking place February 22-23, 2017 at the New York Palace Hotel and at the Cowen Group's 37 th Annual Health Care
OPKO Spain to Start Trial of Once-A-Year Intra-Articular Injectable for Osteoarthritis
Feb 08, 2017
MIAMI , Feb. 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that its wholly owned subsidiary, OPKO Health Spain, has completed development of Enko 1, a patented intra-articular injectable hyaluronic acid and chondroitin sulfate complex to relieve pain and improve
OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer
Feb 07, 2017
Enhances leadership for RAYALDEE ® with deep industry knowledge in nephrology; refocuses commercial structure on field representatives MIAMI , Feb. 07, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced the promotion of Thomas Nusbickel to the newly created position of Chief
OPKO'S GeneDx Announces Research Collaboration with the Wellcome Trust Sanger Institute
Feb 01, 2017
MIAMI , Feb. 01, 2017 (GLOBE NEWSWIRE) -- (Nasdaq:OPK) OPKO Health, Inc. announced today that its subsidiary and business unit, GeneDx, is entering into a collaboration with the Deciphering Developmental Disorder (DDD) study led by the Wellcome Trust Sanger Institute .  The Wellcome Trust Sanger
OPKO Investee Zebra Biologics Announces Collaboration with AbbVie to Discover New Antibody Therapeutics
Jan 10, 2017
MIAMI , Jan. 10, 2017 (GLOBE NEWSWIRE) -- (Nasdaq:OPK) —OPKO Investee, Zebra Biologics Inc. , an emerging biotechnology company of which OPKO owns approximately 28%, announced it has entered into a collaboration with AbbVie to discover agonist antibody therapeutics for inflammatory diseases.
OPKO Announces Initiation of Claros® 1 Clinical Trial for Total PSA
Jan 09, 2017
MIAMI , Jan. 09, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the initiation of a multi-center clinical validation study for the Company's proprietary Total PSA microfluidic assay cassette running on the Claros ® 1 in-office immunoassay analyzer.
OPKO Health to Present at the J.P. Morgan 35th Annual Healthcare Conference
Jan 04, 2017
MIAMI , Jan. 04, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the J.P. Morgan 35 th Annual Healthcare Conference on Wednesday, January 11, 2017 at 9:00 AM (PT) . The presentation will be webcast on the OPKO Investor Relations page of
OPKO Health Provides Update on hGH-CTP Clinical Programs
Dec 30, 2016
Commenced data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults   Initiated Global Pediatric Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Children MIAMI , Dec. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc.
OPKO Health to be Added to the NASDAQ Biotechnology Index
Dec 19, 2016
MIAMI , Dec. 19, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI) effective as of the opening of trading on Monday, December 19, 2016. The NASDAQ Biotechnology Index is designed to track the
OPKO Health to Participate at Three Investment Conferences in December
Nov 30, 2016
MIAMI , Nov. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that its senior management team will host one-on-one investor meetings with institutional investors participating at the following investor conferences in December: Evercore ISI MedTools Investor Conference taking
Displaying 41 - 60 of 363